Drug Profile
Secukinumab - Novartis
Alternative Names: AIN-457; Anti-interleukin 17A monoclonal antibody; Cosentyx; KB-03303A; Kosentikusu; NVP-AIN-457; ScaphoLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Alcon; Novartis
- Developer Beth Israel Deaconess Medical Center; GWT-TUD GmbH; Icahn School of Medicine at Mount Sinai; Novartis
- Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action IL17A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ankylosing spondylitis; Hidradenitis suppurativa; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
- Registered Juvenile rheumatoid arthritis
- Phase III Giant cell arteritis; Graves ophthalmopathy; Polymyalgia rheumatica; Rotator cuff injuries
- Phase II Atopic dermatitis; Discoid lupus erythematosus; Necrobiosis lipoidica; SARS-CoV-2 acute respiratory disease; Tendon injuries
- Discontinued Alopecia areata; Asthma; Crohn's disease; Dry eyes; Lichen planus; Lupus nephritis; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus; Uveitis
Most Recent Events
- 15 Mar 2024 Phase-I clinical trials in Giant cell arteritis in USA (IV) (NCT06130540)
- 15 Mar 2024 Phase-I clinical trials in Polymyalgia rheumatica in USA (IV) (NCT06130540)
- 06 Feb 2024 Novartis plans to file a regulatory submission for Polymyalgia rheumatica in 2026 (Novartis pipeline, February 2024)